Palvella Therapeutics, Inc. (PVLA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Palvella Therapeutics reported revenue of $0. Net income was -$41.7M, or -$3.71 per diluted share. Operating activities generated -$25.0M of cash, leaving -$25.0M of free cash flow. At fiscal year end, Palvella Therapeutics held $59.6M in total assets against $31.6M in total liabilities, including $58.0M of cash and equivalents.
Open the full interactive Palvella Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Palvella Therapeutics Key Stats
| Share Price | $128.51 |
|---|---|
| Market Cap | $1.84B |
| 52-Week Range | $70.43 – $158.13 |
| Shares Outstanding | 14.4 million (basic, 2026 Q2) |
Palvella Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $29.3M | $31.4M | $25.9M | $42.8M | $0 | $0 |
| Operating Income | -$33.9M | -$51.8M | -$43.5M | -$29.8M | -$14.1M | -$38.6M |
| Pre-Tax Income | -$37.1M | -$45.7M | -$33.3M | -$24.5M | -$17.4M | -$41.7M |
| Income Tax | $164,000 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$37.2M | -$45.7M | -$33.3M | -$24.5M | -$17.4M | -$41.7M |
| Diluted EPS | -$54.40 | -$56.80 | — | — | -$7.83 | -$3.71 |
Palvella Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$11.3M | -$12.7M | -$15.8M | -$21.9M |
| Diluted EPS | -$1.03 | -$1.13 | -$1.20 | -$1.52 |
Palvella Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $70.4M | $117.8M | $38.6M | $17.4M | $83.6M | $58.0M |
| Current Assets | $75.7M | $127.6M | $73.4M | $38.7M | $88.2M | $59.0M |
| Total Assets | $105.0M | $153.6M | $95.5M | $38.7M | $88.2M | $59.6M |
| Current Liabilities | $22.1M | $50.6M | $36.6M | $11.9M | $12.0M | $11.3M |
| Total Long-Term Debt | — | — | — | — | $18.4M | $18.4M |
| Total Liabilities | $74.0M | $102.8M | $67.6M | $11.9M | $25.6M | $31.6M |
| Shareholders' Equity | $31.0M | $50.8M | $27.9M | $26.8M | $62.6M | $28.0M |
Palvella Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$45.9M | -$7.7M | -$59.9M | -$53.8M | -$10.8M | -$25.0M |
| Cash From Investing | $39.2M | -$949,000 | -$21.2M | $12.0M | — | — |
| Cash From Financing | $10.1M | $59.1M | $7.2M | $19.8M | $87.1M | -$660,000 |
| Free Cash Flow | -$48.6M | -$8.6M | -$61.0M | -$54.0M | -$10.8M | -$25.0M |
Figures from Palvella Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Palvella Therapeutics financials page for every line item.
Palvella Therapeutics Company Profile
| Ticker | PVLA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wayne, Pennsylvania |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001583648 |
Frequently Asked Questions
What was Palvella Therapeutics' revenue in fiscal 2025?
Palvella Therapeutics (PVLA) reported revenue of $0 for fiscal 2025.
What is Palvella Therapeutics' annual revenue history?
Palvella Therapeutics' annual revenue by fiscal year: 2020: $29.3M; 2021: $31.4M; 2022: $25.9M; 2023: $42.8M; 2024: $0; 2025: $0.
What was Palvella Therapeutics' net income in fiscal 2025?
Palvella Therapeutics reported net income of -$41.7M for fiscal 2025.
What was Palvella Therapeutics' earnings per share (EPS) in fiscal 2025?
Palvella Therapeutics' diluted EPS was -$3.71 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Palvella Therapeutics generate in fiscal 2025?
Palvella Therapeutics generated -$25.0M of free cash flow in fiscal 2025.
What was Palvella Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Palvella Therapeutics reported revenue of $0.
How much debt does Palvella Therapeutics have?
Palvella Therapeutics reported $18.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Palvella Therapeutics are outstanding?
Palvella Therapeutics reported a weighted average of 14.4 million basic shares outstanding in 2026 Q2.
What is Palvella Therapeutics' market cap?
Based on its latest closing price, Palvella Therapeutics (PVLA) has a market capitalization of about $1.84B.
When does Palvella Therapeutics' fiscal year end?
Palvella Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Palvella Therapeutics headquartered?
Palvella Therapeutics lists its business address in Wayne, Pennsylvania in its SEC filings.